title: Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts.
abstract: While the potential importance of hypoxia in limiting the sensitivity of tumor cells to ionizing radiation has long been appreciated, methods for accurately quantifying the number of radiation-resistant hypoxic cells within tumors have been lacking. We have used the pentafluorinated derivative [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)-acet amide] of etanidazole (EF5), which binds selectively to hypoxic cells. The adducts formed between EF5 and cellular proteins in the hypoxic cells were detected using the specific monoclonal antibody (MAb), ELK3-51 conjugated to the flurochrome Cy3, and the number of hypoxic cells was quantified by flow cytometry. To verify the validity of this technique for the detection of hypoxic cells, mice bearing KHT sarcomas were treated with various agents to alter tumor oxygenation and hence vary the fraction of radiobiologically hypoxic tumor cells. The percentage of EF5 binding cells was then compared directly with the clonogenic survival of the tumor cells following radiation treatment under the various pretreatment conditions. The results showed that allowing the mice to breathe carbogen (5% CO2/95% O2) prior to irradiation reduced clonogenic cell survival approx. 6-fold and led to an absence of cells binding high levels of EF5. In contrast, pretreating the tumor-bearing animals with either hydralazine, which decreased tumor blood flow, or phenylhydrazine hydrochloride, which made the mice anemic, increased tumor cell survival following irradiation 2- to 4-fold, indicative of an increase in the fraction of hypoxic tumor cells. EF5 measurements made under identical conditions illustrated a shift in the cells in the tumor to high EF5 binding. Our results demonstrate that flow cytometric measurement by fluorescent MAb binding to EF5 adducts may relate directly to radiobiological hypoxia in KHT tumors measured by conventional methods.
authors.affiliation: Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, NY 14642, USA.
authors.forename: J
authors.initials: J
authors.lastname: Lee
authors.forename: D W
authors.initials: DW
authors.lastname: Siemann
authors.forename: C J
authors.initials: CJ
authors.lastname: Koch
authors.forename: E M
authors.initials: EM
authors.lastname: Lord
mesh_terms: D000740:Anemia / Q000139:chemically induced; D000818:Animals; D000911:Antibodies, Monoclonal; D002245:Carbon Dioxide / Q000008:administration & dosage; D015687:Cell Hypoxia; D002470:Cell Survival / Q000502:physiology / Q000528:radiation effects; D017341:Etanidazole / Q000031:analogs & derivatives* / Q000032:analysis / Q000378:metabolism; D005260:Female; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D006830:Hydralazine / Q000494:pharmacology; D006845:Hydrocarbons, Fluorinated / Q000032:analysis / Q000378:metabolism*; D051379:Mice; D008809:Mice, Inbred C3H; D009368:Neoplasm Transplantation; D010100:Oxygen / Q000008:administration & dosage / Q000378:metabolism*; D010659:Phenylhydrazines / Q000494:pharmacology; D011853:Radiobiology; D012513:Sarcoma, Experimental / Q000098:blood supply / Q000378:metabolism* / Q000532:radiotherapy*; D014665:Vasodilator Agents / Q000494:pharmacology; D005466:Fluorocarbons
chemical_list: D000911:Antibodies, Monoclonal; D002245:Carbon Dioxide; D017341:Etanidazole; D006830:Hydralazine; D006845:Hydrocarbons, Fluorinated; D010100:Oxygen; D010659:Phenylhydrazines; D014665:Vasodilator Agents; C030299:phenylhydrazine; C096011:2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide; D005466:Fluorocarbons; C011700:carbogen